Φορτώνει......
Open-Label Trial of Ranolazine for the Treatment of Paramyotonia Congenita
INTRODUCTION: Paramyotonia congenita (PMC) is a non-dystrophic myotonic disorder that is believed to be caused by a defect in Na(v)1.4 sodium channel inactivation. Ranolazine, which acts by enhancing slow inactivation of sodium channels, has been proposed as a therapeutic option, but in vivo studies...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Muscle Nerve |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6340713/ https://ncbi.nlm.nih.gov/pubmed/30390395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mus.26372 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|